top of page
論文要約

原著論文

原著論文

2020年

  1. Imanishi M, Yamakawa Y, Fukushima K, Ikuto R, Maegawa A, Izawa-Ishizawa Y, Horinouchi Y, Kondo M, Kishuku M, Goda M, Zamami Y, Takechi K, Chuma M, Ikeda Y, Tsuchiya K, Fujino H, Tsuneyama K, Ishizawa K. Fibroblast-specific ERK5 deficiency changes tumor vasculature and exacerbates tumor progression in a mouse model. Naunyn Schmiedebergs Arch Pharmacol. 393(7):1239-1250. 2020.

  2. Tsuchihashi Y, Abe S, Miyamoto L, Tsunematsu H, Izumi T, Hatano A, Okuno H, Yamane M, Yasuoka T, Ikeda Y, Tsuchiya K. Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer. Mol Pharm. 17(4):1049-1058. 2020.

  3. Tsuda T, Imanishi M, Oogoshi M, Goda M, Kihira Y, Horinouchi Y, Zamami Y, Ishizawa K, Ikeda Y, Hashimoto I, Tamaki T, Izawa-Ishizawa Y.Rho-associated protein kinase and cyclophilin a are involved in inorganic phosphate-induced calcification signaling in vascular smooth muscle cells. J Pharmacol Sci. 142(3):109-115. 2020

  4. Hamano H, Niimura T, Horinouchi Y, Zamami Y, Takechi K, Goda M, Imanishi M, Chuma M, Izawa-Ishizawa Y, Miyamoto L, Fukushima K, Fujino H, Tsuchiya K, Ishizawa K, Tamaki T, Ikeda Y (equal contribution & corresponding author). Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway. Toxicol Lett. 318:86-91.2020.

2019年

  1. Hamano H, Mitsui M, Zamami Y, Takechi K, Nimura T, Okada N, Fukushima K, Imanishi M, Chuma M, Horinouchi Y, Izawa-Ishizawa Y, Kirino Y, Nakamura T, Teraoka K, Ikeda Y, Fujino H, Yanagawa H, Tamaki T, Ishizawa K. Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database. Support Care Cancer. 27(3):849-56.2019.

  2. Ikeda Y(corresponding author), Satoh A, Horinouchi Y, Hamano H, Watanabe H, Imao M, Imanishi M, Zamami Y, Takechi K, Izawa-Ishizawa Y, Miyamoto L, Hirayama T, Nagasawa H, Ishizawa K, Aihara KI, Tsuchiya K, Tamaki T. Iron accumulation causes impaired myogenesis correlated with MAPK signaling pathway inhibition by oxidative stress. FASEB J. 33(8):9551-64. 2019

  3. Izawa-Ishizawa Y, Imanishi M, Zamami Y, Toya H, Nagao T, Morishita M, Tsuneyama K, Horinouchi Y, Kihira Y, Takechi K, Ikeda Y, Tsuchiya K, Yoshizumi M, Tamaki T, Ishizawa K. Development of a novel aortic dissection mouse model and evaluation of drug efficacy using in-vivo assays and database analyses. J Hypertens. 37(1):73-83.

  4. Kondo M, Imanishi M, Fukushima K, Ikuto R, Murai Y, Horinouchi Y, Izawa-Ishizawa Y, Goda M, Zamami Y, Takechi K, Chuma M, Ikeda Y, Fujino H, Tsuchiya K, Ishizawa K. Xanthine Oxidase Inhibition by Febuxostat in Macrophages Suppresses Angiotensin II-Induced Aortic Fibrosis. Am J Hypertens. 32(3):249-256.2019.

2018年

  1. Horinouchi Y, Ikeda Y (equal contribution & corresponding author), Fukushima K, Imanishi M, Hamano H, Izawa-Ishizawa Y, Zamami Y, Takechi K, Miyamoto L, Fujino H, Ishizawa K, Tsuchiya K, Tamaki T. Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis. Sci Rep. 8(1):10858.2018.

  2. Imanishi M, Izawa-Ishizawa Y, Sakurada T, Kohara Y, Horinouchi Y, Sairyo E, Zamami Y, Takechi K, Chuma M, Fukushima K, Ikeda Y, Fujino H, Yoshizumi M, Tsuchiya K, Tamaki T, Ishizawa K. Nitrosonifedipine, a Photodegradation Product of Nifedipine, Suppresses Pharmacologically Induced Aortic Aneurysm Formation. Pharmacology. 102(5-6):287-99.2018.

  3. Tsuda K, Miyamoto L, Hamano S, Morimoto Y, Kangawa Y, Fukue C, Kagawa Y, Horinouchi Y, Xu W, Ikeda Y Tamaki T, Tsuchiya K. Mechanisms of the pH- and Oxygen-Dependent Oxidation Activities of Artesunate. Biol Pharm Bull. 41(4):555-63.2018.

  4. Hamano H, Ikeda Y(equal contribution & corresponding author), Watanabe H, Horinouchi Y, Izawa-Ishizawa Y, Imanishi M, Zamami Y, Takechi K, Miyamoto L, Ishizawa K, Tsuchiya K, Tamaki T. The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease. Nephrol Dial Transplant. 33(4):586-97. 2018.

  5. Xu W, Miyamoto L, Aihara H, Yamaoka T, Tanaka N, Tsuchihashi Y, Ikeda Y, Tamaki T, Kashiwada Y, Tsuchiya K. Methanol extraction fraction from Citrus Sudachi peel exerts lipid reducing effects in cultured cells. J Med Invest. 65(3.4):225-30.2018.

2017年以前
（鉄に関する論文）

  1. Ikeda Y(corresponding author), Horinouchi Y, Hamano H, Hirayama T, Kishi S, Izawa-Ishizawa Y, Imanishi M, Zamami Y, Takechi K, Miyamoto L, Ishizawa K, Aihara KI, Nagasawa H, Tsuchiya K, Tamaki T. Dietary iron restriction alleviates renal tubulointerstitial injury induced by protein overload in mice. Sci Rep. 7(1):10621. 2017.

  2. Oshima K, Ikeda Y(equal contribution & corresponding author), Horinouchi Y, Watanabe H, Hamano H, Kihira Y, Kishi S, Izawa-Ishizawa Y, Miyamoto L, Hirayama T, Nagasawa H, Ishizawa K, Tsuchiya K, Tamaki T. Iron suppresses erythropoietin expression via oxidative stress-dependent hypoxia-inducible factor-2 alpha inactivation. Lab Invest. 97(5):555-66. 2017.

  3. Ikeda Y(corresponding author), Imao M, Satoh A, Watanabe H, Hamano H, Horinouchi Y, Izawa-Ishizawa Y, Kihira Y, Miyamoto L, Ishizawa K, Tsuchiya K, Tamaki T. Iron-induced skeletal muscle atrophy involves an Akt-forkhead box O3-E3 ubiquitin ligase-dependent pathway. J Trace Elem Med Biol. 35:66-76. 2016.

  4. Yamano N, Ikeda Y, Sakama M, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, Miyamoto L, Tomita S, Tsuchiya K, Tamaki T. A long-term high-fat diet changes iron distribution in the body, increasing iron accumulation specifically in the mouse spleen. J Nutr Sci Vitaminol (Tokyo). 61(1):20-7.2015.

  5. Tajima S, Ikeda Y(corresponding author),, Enomoto H, Imao M, Horinouchi Y, Izawa-Ishizawa Y, Kihira Y, Miyamoto L, Ishizawa K, Tsuchiya K, Tamaki T. Angiotensin II alters the expression of duodenal iron transporters, hepatic hepcidin, and body iron distribution in mice. Eur J Nutr. 54(5):709-19.2015.

  6. Ikeda Y(corresponding author),, Ozono I, Tajima S, Imao M, Horinouchi Y, Izawa-Ishizawa Y, Kihira Y, Miyamoto L, Ishizawa K, Tsuchiya K, Tamaki T. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction. PLoS One. 9(2):e89355.2014.

  7. Ikeda Y(corresponding author),, Enomoto H, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, Tomita S, Tsuchiya K, Tamaki T. Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice. Am J Physiol Renal Physiol. 304(7):F1028-36. 2013.

  8. Tajima S, Ikeda Y(equal contribution & corresponding author), Sawada K, Yamano N, Horinouchi Y, Kihira Y, Ishizawa K, Izawa-Ishizawa Y, Kawazoe K, Tomita S, Minakuchi K, Tsuchiya K, Tamaki T. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab. 302(1):E77-86. 2012.

  9. Ikeda Y(corresponding author),, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, Tomita S, Tsuchiya K, Tamaki T. Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes. PLoS One. 7(7):e40465.2012.

  10. Ikeda Y(corresponding author),, Tajima S, Yoshida S, Yamano N, Kihira Y, Ishizawa K, Aihara K, Tomita S, Tsuchiya K, Tamaki T. Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function. Atherosclerosis. 2215(2):339-47. 2011.

  11. Tajima S, Tsuchiya K, Horinouchi Y, Ishizawa K, Ikeda Y, Kihira Y, Shono M, Kawazoe K, Tomita S, Tamaki T. Effect of angiotensin II on iron-transporting protein expression and subsequent intracellular labile iron concentration in human glomerular endothelial cells. Hypertens Res. 33(7):713-21.2010.

​（男性ホルモンに関する論文）

  1. Yoshida S, Aihara K, Ikeda Y, Sumitomo-Ueda Y, Uemoto R, Ishikawa K, Ise T, Yagi S, Iwase T, Mouri Y, Sakari M, Matsumoto T, Takeyama K, Akaike M, Matsumoto M, Sata M, Walsh K, Kato S, Matsumoto T. Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation. 128(1):60-71.2013

  2. Ikeda Y, Aihara K, Akaike M, Sato T, Ishikawa K, Ise T, Yagi S, Iwase T, Ueda Y, Yoshida S, Azuma H, Walsh K, Tamaki T, Kato S, Matsumoto T. Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice.
    Mol Endocrinol. 24(7):1338-48. 2010.

  3. Yoshida S, Aihara K, Azuma H, Uemoto R, Sumitomo-Ueda Y, Yagi S, Ikeda Y, Iwase T, Nishio S, Kawano H, Miki J, Yamada H, Hirata Y, Akaike M, Sata M, Matsumoto T. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis. 212(1):310-5. 2010.

  4. Ikeda Y, Aihara K, Yoshida S, Sato T, Yagi S, Iwase T, Sumitomo Y, Ise T, Ishikawa K, Azuma H, Akaike M, Kato S, Matsumoto T.Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling.
    Endocrinology. 150(6):2857-64. 2009.

  5. Ikeda Y, Aihara K, Sato T, Akaike M, Yoshizumi M, Suzaki Y, Izawa Y, Fujimura M, Hashizume S, Kato M, Yagi S, Tamaki T, Kawano H, Matsumoto T, Azuma H, Kato S, Matsumoto T.Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem. 19;280(33):29661-6. 2005.

業績: リスト
業績: ファイル
論文要約

総　説

英文総説

  1. Yoshida S, Ikeda Y, Aihara KI. Roles of the Androgen-Androgen Receptor System in Vascular Angiogenesis. J Atheroscler Thromb 23: 257-265, 2016.

  2. Yagi S, Aihara K, Ikeda Y, Akaike M, Sata M, Matsumoto T. Effects of statins on cardiorenal syndrome. Int J Vasc Med 2012: 162545, 2012.

  3. Ikeda Y, Aihara KI, Yoshida S, Akaike M, Matsumoto T. Effects of androgens on cardiovascular remodeling. J Endocrinol 2012.

  4. Tomita S, Kihira Y, Imanishi M, Fukuhara Y, Imamura Y, Ishizawa K, Ikeda Y, Tsuchiya K, Tamaki T. Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery:inflammatory responses of hypoxia-inducible factor 1alpha (HIF-1alpha) in T cells observed in development of vascular remodeling. J Pharmacol Sci 115: 433-439, 2011.

  5. Ishizawa K, Yoshizumi M, Kawai Y, Terao J, Kihira Y, Ikeda Y, Tomita S, Minakuchi K, Tsuchiya K, Tamaki T. Pharmacology in health food: metabolism of quercetin in vivo and its protective effect against arteriosclerosis. J Pharmacol Sci 115: 466-470, 2011.

  6. Aihara K, Ikeda Y, Yagi S, Akaike M, Matsumoto T. Transforming Growth Factor-beta1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome. Cardiol Res Pract 2011: 175381, 2010.

  7. Tsuchiya K, Tomita S, Ishizawa K, Abe S, Ikeda Y, Kihira Y, Tamaki T. Dietary nitrite ameliorates renal injury in L-NAME-induced hypertensive rats. Nitric Oxide 22: 98-103, 2010.

和文総説

  1. 池田 康将. 腎疾患と鉄代謝異常. 腎臓内科. 11(2):146-152,2020.

  2. Horinouchi Y, Ikeda Y, Tamaki T. [Body iron accumulation in obesity, diabetes and its complications, and the possibility of therapeutic application by iron regulation]. Nihon Yakurigaku Zasshi. 154(6):316-21. 2019.

  3. 堀ノ内裕也, 池田 康将, 玉置 俊晃．肥満・糖尿病とその合併症における生体内鉄蓄積と鉄制限による治療応用への可能性.日本薬理学雑誌. 154(6): 316-321, 2019.

  4. 池田 康将. 糖尿病における微量栄養素「鉄」の役割. 四国医学雑誌1,2:13-20,2018.

  5. 今西 正樹, 石澤 啓介, 櫻田 巧, 石澤 有紀, 山野 範子, 木平 孝高, 池田 康将, 土屋 浩一郎, 玉置 俊晃. 酸化ストレス制御を基盤とする新規心腎血管障害治療薬の開発. 薬学雑誌134(6): 715-719, 2014.

  6. 池田 康将, 土屋 浩一郎, 玉置 俊晃. 抗酸化薬. 腎・高血圧の最新治療 3:93-99,2014.

  7. 池田 康将, 土屋 浩一郎, 玉置 俊晃.糖尿病と食事由来金属元素.糖尿病 56:919-921,2013

  8. 池田 康将, 田島 壮一郎, 土屋 浩一郎, 玉置 俊. Iron metabolism in the progression of adipocyte hypertrophy. 細胞 44:282-286 5, 2012年6月

  9. 池田 康将, 田島 壮一郎, 山野 範子, 土屋 浩一郎, 玉置 俊晃. 循環器疾患と糖尿病における生体内鉄の意義. 血管 34:75-85, 2011.

  10. 冨田 修平, 今西 正樹, 櫻田 巧, 山野 範子, 木平 孝高, 池田 康将, 玉置 俊晃.生体の低酸素応答と病態 -血管リモデリングにおける転写因子HIFの関与-,四国医学雑誌 67:3-6,2011.

  11. 粟飯原 賢一, 池田 康将, 松本 俊夫.【慢性心不全の分子機構 新しい治療戦略を求めて】 性ステロイドと心保護作用. 循環器科 59:579-584,2006.

業績: リスト
論文要約

著書・症例報告

著書

  1. 池田 康将, 堀ノ内祐也. カラー新しい薬理学（8章 血液・造血器・リンパ系）.341-362, 西村書店, 2018年5月

  2. 池田 康将, 玉置 俊晃.Annual Review 2015腎臓---腎疾患と鉄代謝異常---,株式会社 中外医学社, 2015年1月.     

  3. 宮本 理人, 山根 萌, 冨田 洋輔, 石澤 啓介, 池田 康将, 玉置 俊晃, 土屋 浩一郎.ヒト腎糸球体内皮細胞における亜硝酸塩によるAMPK-eNOS活性化経路の検討, 腎とフリーラジカル第12集.127-130,株式会社 東京医学社, 2014年10月.

  4. 池田 康将, 田島 壮一郎, 木平 孝高, 石澤 有紀, 石澤 啓介, 冨田 修平, 土屋 浩一郎, 玉置 俊晃. 腎とフリーラジカル第11集, --- 脂肪組織肥大進展における鉄キレート剤の効果 ---.155-159, 株式会社 東京医学社, 2013年1月.

  5.  櫻田 巧, 石澤 啓介, 今西 正樹, 藤井 聖子, 谷口 順平, 石澤 有紀, 宮本 理人, 木平 孝高, 池田 康将, 冨田 修平, 水口 和生, 土屋 浩一郎, 玉置 俊晃.腎とフリーラジカル第11集, --- NitrosonifedipineはangiotensinⅡによるマウス血管リモデリングを抑制する ---,79-81,株式会社 東京医学社, 2013年1月.    

  6. 土屋 浩一郎, 石澤 啓介, 宮本 理人, 堀ノ内 裕也, 池田 康将, 木平 孝高, 冨田 修平, 玉置 俊晃. 腎とフリーラジカル第11集, --- 亜硝酸塩による腎保護作用 ---,31-33,株式会社 東京医学社, 2013年1月.     

  7.  田島 壮一郎, 土屋 浩一郎, 濱本 磨以, 久住 祥子, 堀ノ内 裕也, 八木 祐子, 櫻田 巧, 石澤 啓介, 池田 康将, 木平 孝高, 冨田 修平, 玉置 俊晃. 腎とフリーラジカル第10集, --- アンジオテンシンII刺激による細胞内遊離鉄を介した酸化ストレス増強機構 ---,59-63,株式会社 東京医学社, 2010年6月

症例報告（英文のみ）

  1. Yagi S, Akaike M, Fujimura M, Ise T, Yoshida S, Sumitomo Y, Ikeda Y, Iwase T, Aihara K, Azuma H, Kurushima A, Ichikawa Y, Kitagawa T, Kimura T, Nishiuchi T, Matsumoto T. Infective endocarditis caused by lactobacillus. Intern Med 47: 1113-1116, 2008.

  2. Yagi S, Akaike M, Ozaki S, Moriya C, Takeuchi K, Hara T, Fujimura M, Sumitomo Y, Iwase T, Ikeda Y, Aihara K, Kimura T, Nishiuchi T, Abe M, Matsumoto T. Improvement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL cardiac amyloidosis. Intern Med 46: 1705-1710, 2007.

  3. Ikeda Y, Yagi S, Yamaguchi H, Fujimura M, Hashizume S, Aihara K, Akaike M, Azuma H, Matsumoto T. Intra-vascular ultrasound findings of diffuse coronary atherosclerotic change in systemic lupus erythematosus with secondary antiphospholipid syndrome. Circ J 70: 1082-1085, 2006.

  4. Watanabe T, Fujinaga H, Ikeda Y, Higashi T, Murakami M, Kawahara K, Hayashi I, Niki T, Shigekiyo T, Wakatsuki T. Acute myocardial infarction in a patient with essential thrombocythemia who underwent successful stenting--a case report. Angiology 56: 771-774, 2005.

  5. Ikeda Y, Fujinaga H, Niki T. Successful percutaneous coronary intervention for acute myocardial infarction caused by simultaneous occlusion of two major coronary arteries in patients with diabetes mellitus. A report of two cases. Acta Cardiol 60: 225-228, 2005.

  6. Aihara K, Azuma H, Ikeda Y, Akaike M, Abe M, Sugihara T, Matsumoto T. Successful combination therapy--flunarizine, pentoxifylline, and cholestyramine--for spur cell anemia. Int J Hematol 73: 351-355, 2001.

業績: リスト
bottom of page